Acquisitions - Acquisition of Scilex Pharmaceuticals Inc. (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Feb. 28, 2018	Sep. 11, 2017	Nov. 08, 2016	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Acquisition consideration payable					$ 53,209	$ 48,362
Noncontrolling interests					7,042	6,465
Goodwill					$ 38,298	$ 41,548
Overstatement of acquisition consideration payable [Member]
Business Acquisition [Line Items]
Amount of misstatement in current year financial statements				$ 6,500
Overstatement of intangible assets [Member]
Business Acquisition [Line Items]
Amount of misstatement in current year financial statements				6,700
Overstatement of goodwill [Member]
Business Acquisition [Line Items]
Amount of misstatement in current year financial statements				4,600
Overstatement of deferred income tax liability [Member]
Business Acquisition [Line Items]
Amount of misstatement in current year financial statements				2,800
Overstatement of additional paid on capital [Member]
Business Acquisition [Line Items]
Amount of misstatement in current year financial statements				600
Overstatement of noncontrolling interest [Member]
Business Acquisition [Line Items]
Amount of misstatement in current year financial statements				$ 1,400
Itochu [Member]
Business Acquisition [Line Items]
Noncontrolling interest ownership percentage			23.00%
Scilex Pharmaceuticals, Inc [Member]
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired			72.00%
Business acquisition, common stock consideration		$ 1,400	$ 4,800
Issuance of common stock upon acquisition, shares		754,930	754,911
Acquisition consideration payable			$ 33,500
Total purchase consideration			38,200
Noncontrolling interests			12,300
Identifiable assets recognized			54,900
Liabilities assumed in a business acquisition			17,900
Deferred tax liabilities assumed			13,900
Goodwill			13,500
Scilex Pharmaceuticals, Inc [Member] | Acquired in-process research and development [Member]
Business Acquisition [Line Items]
Assets acquired			21,900
Scilex Pharmaceuticals, Inc [Member] | Patent rights [Member]
Business Acquisition [Line Items]
Assets acquired			$ 32,600
Scilex Pharmaceuticals, Inc [Member] | Upon FDA acceptance [Member]
Business Acquisition [Line Items]
Discounted rate on consideration transferred			10.00%
Undiscounted purchase consideration			$ 47,800
Scilex Pharmaceuticals, Inc [Member] | Upon FDA acceptance [Member] | Maximum [Member]
Business Acquisition [Line Items]
Stock price (USD per share)			$ 25.32
Scilex Pharmaceuticals, Inc [Member] | Upon FDA acceptance [Member] | Minimum [Member]
Business Acquisition [Line Items]
Stock price (USD per share)			$ 6.33
Scilex Pharmaceuticals, Inc [Member] | FDA approval [Member]
Business Acquisition [Line Items]
Adjusted base consideration percentage			80.00%
Maximum percentage of common stock issued in connection with acquisition			4.99%
Scilex Pharmaceuticals, Inc [Member] | FDA approval [Member] | Subsequent event [Member]
Business Acquisition [Line Items]
Issuance of common stock upon acquisition, shares	1,381,346
Total purchase consideration	$ 38,200
Scilex Pharmaceuticals, Inc [Member] | FDA approval [Member] | Maximum [Member]
Business Acquisition [Line Items]
Stock price (USD per share)			$ 25.32
Scilex Pharmaceuticals, Inc [Member] | FDA approval [Member] | Minimum [Member]
Business Acquisition [Line Items]
Stock price (USD per share)			$ 6.33